1例希罗达致Ⅲ度手足综合征的循证护理_《中国循证医学杂志》

作者：

陈华英 ,  李继平

1. 四川大学华西医院肿瘤一病房（成都 610041）；2. 四川大学华西医院护理部;

关键词：

卡培他滨手足综合征循证护理

DOI：

10.7507/1672-2531.20080197

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　针对1 例由卡培他滨（希罗达）所致的Ⅲ度手足综合征的乳腺癌患者，检索当前的最佳证据，寻求缓解病人症状和体征的护理方法。
方法　计算机检索Cochrane图书馆（2008年第1期）、ACP Journal Club（1991 ～ 2008）、MEDLINE（1966 ～ 2008）、CBMdisc（1995 ～ 2008），收集有关卡培他滨（希罗达）所致的Ⅲ度手足综合征的护理方法的文献，并对所获证据进行评价。
结果　对由卡培他滨所致的Ⅲ度手足综合征的患者，有两种有效措施：① 停药或调整药物剂量，并同时进行对症支持治疗和护理。② 不停药或调整药物剂量，改用中草药治疗。我们遵循证据并结合患者意愿，对患者进行停药和对症支持治疗和护理，两周后患者恢复良好。
结论　对于由卡培他滨引起的Ⅲ度手足综合征患者，可以采用停药和对症支持的治疗和护理措施来缓解患者症状与体征。

引用本文： 陈华英,李继平. 1例希罗达致Ⅲ度手足综合征的循证护理. 中国循证医学杂志, 2008, 08(10): 898-900. doi: 10.7507/1672-2531.20080197 复制

1.	Courneya KS, Friedenreich CM. Physical exercise and qual ity of life following cancer diagnosis: a literature review. Annals of Behavioural Medicine, 1999, 21: 171-179.
2.	Wilmoth MC, Coleman EA, Smith SC, et al. Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum, 2004, 31: 1069-1075.
3.	Irwin M, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma. Cancer, 2003, 97: 1746-1757.
4.	Irwin M, McTiernan A, Bernstein L, et al. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc, 2004, 36: 1484-1491.
5.	Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 2003, 14(12): 1735-1743.
6.	王玲, 焦智民, 李平. 中药内服外洗治疗希罗达所致中重度手足综合征8例. 中医研究, 2006, 19(4): 40-42.
7.	王涛, 江泽飞, 宋三泰, 等. 希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理.癌症进展杂志, 2004, 2(4): 258-260.
8.	Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S31-40.
9.	王琰, 徐瑞荣. 希罗达所致手足综合征中、西医防治措施研究进展. 中国中西医结合杂志, 2007, 27(2): 182-184.
10.	Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract, 2006, 12(3): 131-141.
11.	Marsé H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S16-30.
12.	Lee SD, Kim HJ, Hwang SJ, et al. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med, 2007, 22(2): 109-112.
13.	Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis, 2004, 73(2): 101.
14.	肖凤霞. 口服希罗达所致手足综合征的护理. 现代护理, 2006, 12(21): 21-22.
15.	王磊. 希罗达(卡培他滨)致严重手足综合征1例. 中国药物应用与监测, 2007, 3: 98.
16.	杨圣菊, 陈晓栋, 王建力. 卡培他滨引起Ⅲ度手足综合征1例. 临床皮肤科杂志, 2007, 36(4): 250.
17.	Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome.Invest New Drugs. 2007 Sep 21 [Epub ahead of print].
18.	Kern E, Schmidinger M, Locker GJ, et al. Management of capecitabine-induced hand-foot syndrome by local phytotherapy. Wien Med Wochenschr, 2007, 157(13-14): 337-42.

1. Courneya KS, Friedenreich CM. Physical exercise and qual ity of life following cancer diagnosis: a literature review. Annals of Behavioural Medicine, 1999, 21: 171-179.
2. Wilmoth MC, Coleman EA, Smith SC, et al. Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum, 2004, 31: 1069-1075.
3. Irwin M, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma. Cancer, 2003, 97: 1746-1757.
4. Irwin M, McTiernan A, Bernstein L, et al. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc, 2004, 36: 1484-1491.
5. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 2003, 14(12): 1735-1743.
6. 王玲, 焦智民, 李平. 中药内服外洗治疗希罗达所致中重度手足综合征8例. 中医研究, 2006, 19(4): 40-42.
7. 王涛, 江泽飞, 宋三泰, 等. 希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理.癌症进展杂志, 2004, 2(4): 258-260.
8. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S31-40.
9. 王琰, 徐瑞荣. 希罗达所致手足综合征中、西医防治措施研究进展. 中国中西医结合杂志, 2007, 27(2): 182-184.
10. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract, 2006, 12(3): 131-141.
11. Marsé H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs, 2004, 8(Suppl 1): S16-30.
12. Lee SD, Kim HJ, Hwang SJ, et al. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med, 2007, 22(2): 109-112.
13. Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis, 2004, 73(2): 101.
14. 肖凤霞. 口服希罗达所致手足综合征的护理. 现代护理, 2006, 12(21): 21-22.
15. 王磊. 希罗达(卡培他滨)致严重手足综合征1例. 中国药物应用与监测, 2007, 3: 98.
16. 杨圣菊, 陈晓栋, 王建力. 卡培他滨引起Ⅲ度手足综合征1例. 临床皮肤科杂志, 2007, 36(4): 250.
17. Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome.Invest New Drugs. 2007 Sep 21 [Epub ahead of print].
18. Kern E, Schmidinger M, Locker GJ, et al. Management of capecitabine-induced hand-foot syndrome by local phytotherapy. Wien Med Wochenschr, 2007, 157(13-14): 337-42.

《中国循证医学杂志》

1例希罗达致Ⅲ度手足综合征的循证护理

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

1例希罗达致Ⅲ度手足综合征的循证护理

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料